Ovarian Cancer is one of the main cancers observed in females. There has been long research on different drugs that can treat this type of cancer. Out of all, the given the main renowned drug in the market is bevacizumab. But the testing can go beyond, and hence one can extend the research of the usage of this drug. In this trial, there has been detailed research on the double and more progression of the usage of bevacizumab. The effects after the first line usage are very much explained out here.
406 patients were taken into the research, and then two different groups were divided with 203 each. One hundred thirty patients (64%) in the bevacizumab group and 131 (65%) in the standard chemotherapy group had progressed after receiving a last dose of platinum more than 12 months before, and 146 patients (72%) in the bevacizumab group and 147 (72%) in the standard chemotherapy group. Most common grade 3–4 adverse events were hypertension. 68 patients (33%) died in the standard chemotherapy group, and 79 (39%) died in the bevacizumab group
In the last, it clearly shows that if one continues bevacizumab after the first line, it can be very beneficial in extending the survival time.
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(20)30637-9/fulltext
